Department of Urology, AKH-General Hospital, Krankenhausstr. 9, 4020 Linz, Austria.
Anticancer Res. 2011 Mar;31(3):985-90.
To evaluate 15-year experience with patients treated with transurethral resection (TUR) of a bladder tumor (TURBT) followed by radiochemotherapy (RCT) or radiation (RT) and to describe the association of different parameters with clinical outcome.
Bladder cancer patients (473) who underwent TURBT and RCT or RT with curative intent between 1982 and 2007 in our clinic were evaluated. The clinical course, operative and pathological characteristics and the long-term clinical outcome were assessed.
Complete remission (CR) was achieved in 70.4% of the patients. The 5-, 10- and 15-year overall survival rates were 49%, 30% and 19%, respectively. Long-term results were significantly affected by pT stage, lymphatic vessel invasion, residual tumor status, lymph node metastasis, kind of therapy (RCT vs. RT), and the response as confirmed by restaging TUR after RCT/RT.
Organ-preservation therapy in patients with bladder cancer is a valid option compared to radical cystectomy in selected patients, ideally with early-stage bladder cancer, in whom a complete transurethral resection of the tumor can be accomplished and radiochemotherapy is superior to radiation for favorable long-term outcome.
评估 15 年来接受经尿道膀胱肿瘤切除术(TURBT)联合放化疗(RCT)或放疗(RT)治疗的患者的经验,并描述不同参数与临床结果的关系。
对 1982 年至 2007 年间在我院接受 TURBT 联合根治性 RCT 或 RT 的膀胱癌患者(473 例)进行评估。评估其临床过程、手术和病理特征以及长期临床结果。
70.4%的患者达到完全缓解(CR)。5 年、10 年和 15 年的总生存率分别为 49%、30%和 19%。pT 分期、淋巴管浸润、肿瘤残留状态、淋巴结转移、治疗方式(RCT 与 RT)以及 RCT/RT 后再次评估确认的反应等因素均显著影响长期结果。
与根治性膀胱切除术相比,在选择合适的患者时,膀胱癌的保器官治疗是一种有效的选择,这些患者最好为早期膀胱癌,能够完全经尿道切除肿瘤,放化疗优于放疗,可获得较好的长期结果。